The Knockdown of LncRNA DLGAP1-AS2 Suppresses Osteosarcoma Progression by Inhibiting Aerobic Glycolysis Via the MiR-451a/HK2 Axis

Overview

Journal Cancer Sci

Specialty Oncology

Date 2023 Oct 11

PMID 37817462

Authors

Changjun Zheng

Ronghang Li

Shuang Zheng

Hongjuan Fang

Meng Xu

Lei Zhong

Affiliations

Soon will be listed here.

Abstract

Osteosarcoma (OS) is one of the most aggressive bone tumors worldwide. Emerging documents have shown that long noncoding RNAs (lncRNAs) elicit crucial regulatory functions in the process of tumorigenesis. LncRNA DLGAP1-AS2 is recognized as a regulator in several types of cancers, but its biological functions and molecular mechanisms in OS remain to be elucidated. RT-qPCR and In situ hybridization (ISH) were used to evaluate DLGAP1-AS2 expression in OS samples. Western blotting was used for the measurement of the protein levels of hexokinase 2 (HK2) and epithelial-mesenchymal transition (EMT)-related markers. The proliferation of OS cells was determined using a CCK-8 assay and EdU assay. TUNEL assay and flow cytometry were performed to assess OS cell apoptosis. Glucose metabolism in vitro assays were used. The binding relations among miR-451a, HK2, and DLGAP1-AS2 were validated by luciferase reporter assay. The cellular distribution of DLGAP1-AS2 in OS cells was determined by FISH and subcellular fractionation assays. Mouse xenograft models were established to perform the experiments in vivo. We found that DLGAP1-AS2 expression was upregulated in OS tissues and cells. Downregulation of DLGAP1-AS2 expression suppressed the malignancy of OS cells by restraining cell proliferation, the EMT process, invasiveness, migration, and aerobic glycolysis and accelerating apoptotic behaviors. Of note, silenced DLGAP1-AS2 restrained tumor growth and metastasis in vivo. However, DLGAP1-AS2 overexpression accelerated the progression of OS. We further found that DLGAP1-AS2 upregulation was induced by hypoxia and low glucose. Additionally, DLGAP1-AS2 bound to miR-451a to upregulate HK2 expression. Rescue assays revealed that the DLGAP1-AS2/miR-451a/HK2 axis contributed to OS cell malignancy by promoting aerobic glucose metabolism. Overall, these findings revealed a new regulatory pathway where DLGAP1-AS2 upregulated HK2 expression by sponging miR-451a to accelerate OS development.

Citing Articles

Deciphering the oncogenic network: how C1QTNF1-AS1 modulates osteosarcoma through miR-34a-5p and glycolytic pathways.

Zhang Y, Lun H, Zhu N, Yang N, Ding K, Chen B Front Oncol. 2025; 14():1485605.

PMID: 39850812 PMC: 11754200. DOI: 10.3389/fonc.2024.1485605.

Osteosarcoma in a ceRNET perspective.

Mosca N, Alessio N, Di Paola A, Marrapodi M, Galderisi U, Russo A J Biomed Sci. 2024; 31(1):59.

PMID: 38835012 PMC: 11151680. DOI: 10.1186/s12929-024-01049-y.

Emerging roles of long non-coding RNAs in osteosarcoma.

Liao X, Wei R, Zhou J, Wu K, Li J Front Mol Biosci. 2024; 11:1327459.

PMID: 38516191 PMC: 10955361. DOI: 10.3389/fmolb.2024.1327459.

Decoding the Impact of Tumor Microenvironment in Osteosarcoma Progression and Metastasis.

Nirala B, Yamamichi T, Petrescu D, Shafin T, Yustein J Cancers (Basel). 2023; 15(20).

PMID: 37894474 PMC: 10605493. DOI: 10.3390/cancers15205108.

The knockdown of lncRNA DLGAP1-AS2 suppresses osteosarcoma progression by inhibiting aerobic glycolysis via the miR-451a/HK2 axis.

Zheng C, Li R, Zheng S, Fang H, Xu M, Zhong L Cancer Sci. 2023; 114(12):4747-4762.

PMID: 37817462 PMC: 10728003. DOI: 10.1111/cas.15989.

References

Ghafouri-Fard S, Shirvani-Farsani Z, Hussen B, Taheri M . The critical roles of lncRNAs in the development of osteosarcoma. Biomed Pharmacother. 2021; 135:111217. DOI: 10.1016/j.biopha.2021.111217. View

Sun Y, Hu L, Zheng H, Bagnoli M, Guo Y, Rupaimoole R . MiR-506 inhibits multiple targets in the epithelial-to-mesenchymal transition network and is associated with good prognosis in epithelial ovarian cancer. J Pathol. 2014; 235(1):25-36. PMC: 4268369. DOI: 10.1002/path.4443. View

Hua Q, Jin M, Mi B, Xu F, Li T, Zhao L . LINC01123, a c-Myc-activated long non-coding RNA, promotes proliferation and aerobic glycolysis of non-small cell lung cancer through miR-199a-5p/c-Myc axis. J Hematol Oncol. 2019; 12(1):91. PMC: 6728969. DOI: 10.1186/s13045-019-0773-y. View

Liang X, Zhao Y, Fang Z, Shao N, Zhai D, Zhang M . DLGAP1-AS2 promotes estrogen receptor signalling and confers tamoxifen resistance in breast cancer. Mol Biol Rep. 2022; 49(5):3939-3947. DOI: 10.1007/s11033-022-07244-0. View

Zheng C, Li R, Zheng S, Fang H, Xu M, Zhong L . The knockdown of lncRNA DLGAP1-AS2 suppresses osteosarcoma progression by inhibiting aerobic glycolysis via the miR-451a/HK2 axis. Cancer Sci. 2023; 114(12):4747-4762. PMC: 10728003. DOI: 10.1111/cas.15989. View

Hang Q, Lu J, Zuo L, Liu M . Linc00641 promotes the progression of gastric carcinoma by modulating the miR-429/Notch-1 axis. Aging (Albany NY). 2021; 13(6):8497-8509. PMC: 8034904. DOI: 10.18632/aging.202661. View

Tam W, Weinberg R . The epigenetics of epithelial-mesenchymal plasticity in cancer. Nat Med. 2013; 19(11):1438-49. PMC: 4190672. DOI: 10.1038/nm.3336. View

Ye X, Weinberg R . Epithelial-Mesenchymal Plasticity: A Central Regulator of Cancer Progression. Trends Cell Biol. 2015; 25(11):675-686. PMC: 4628843. DOI: 10.1016/j.tcb.2015.07.012. View

Zheng S, Li M, Miao K, Xu H . lncRNA GAS5-promoted apoptosis in triple-negative breast cancer by targeting miR-378a-5p/SUFU signaling. J Cell Biochem. 2019; 121(3):2225-2235. DOI: 10.1002/jcb.29445. View

10.

Li Y, Liu J, Zhou J, Chen R, Cen C . LncRNA HULC induces the progression of osteosarcoma by regulating the miR-372-3p/HMGB1 signalling axis. Mol Med. 2020; 26(1):26. PMC: 7081592. DOI: 10.1186/s10020-020-00155-5. View

11.

Li X, Zhang Z, Zhang Y, Cao Y, Wei H, Wu Z . Upregulation of lactate-inducible snail protein suppresses oncogene-mediated senescence through p16 inactivation. J Exp Clin Cancer Res. 2018; 37(1):39. PMC: 5828408. DOI: 10.1186/s13046-018-0701-y. View

12.

Zhao D, Wang S, Chu X, Han D . LncRNA HIF2PUT inhibited osteosarcoma stem cells proliferation, migration and invasion by regulating HIF2 expression. Artif Cells Nanomed Biotechnol. 2019; 47(1):1342-1348. DOI: 10.1080/21691401.2019.1596934. View

13.

Wang Y, Bao D, Wan L, Zhang C, Hui S, Guo H . Long non-coding RNA small nucleolar RNA host gene 7 facilitates the proliferation, migration, and invasion of esophageal cancer cells by regulating microRNA-625. J Gastrointest Oncol. 2021; 12(2):423-432. PMC: 8107616. DOI: 10.21037/jgo-21-147. View

14.

Shi Y, Zhang Y, Ran F, Liu J, Lin J, Hao X . Let-7a-5p inhibits triple-negative breast tumor growth and metastasis through GLUT12-mediated warburg effect. Cancer Lett. 2020; 495:53-65. DOI: 10.1016/j.canlet.2020.09.012. View

15.

Ritter J, Bielack S . Osteosarcoma. Ann Oncol. 2010; 21 Suppl 7:vii320-5. DOI: 10.1093/annonc/mdq276. View

16.

Zhang Y, Yuan Y, Wu H, Xie Z, Wu Y, Song X . Effect of verbascoside on apoptosis and metastasis in human oral squamous cell carcinoma. Int J Cancer. 2018; 143(4):980-991. DOI: 10.1002/ijc.31378. View

17.

Meng F, Wu L, Dong L, Mitchell A, Block C, Liu J . EGFL9 promotes breast cancer metastasis by inducing cMET activation and metabolic reprogramming. Nat Commun. 2019; 10(1):5033. PMC: 6834558. DOI: 10.1038/s41467-019-13034-3. View

18.

Chu Z, Huo N, Zhu X, Liu H, Cong R, Ma L . FOXO3A-induced LINC00926 suppresses breast tumor growth and metastasis through inhibition of PGK1-mediated Warburg effect. Mol Ther. 2021; 29(9):2737-2753. PMC: 8417517. DOI: 10.1016/j.ymthe.2021.04.036. View

19.

Yang C, Huang D, Ma C, Ren J, Fu L, Cheng C . Identification of Pathogenic Genes and Transcription Factors in Osteosarcoma. Pathol Oncol Res. 2019; 26(2):1041-1048. DOI: 10.1007/s12253-019-00645-w. View

20.

Fu D, Lu C, Qu X, Li P, Chen K, Shan L . LncRNA TTN-AS1 regulates osteosarcoma cell apoptosis and drug resistance via the miR-134-5p/MBTD1 axis. Aging (Albany NY). 2019; 11(19):8374-8385. PMC: 6814585. DOI: 10.18632/aging.102325. View